Citi Downgrades Bristol-Myers Squibb Co. (BMY) to Neutral
Tweet
Share
E-mail
Get Alerts BMY Hot Sheet
Price: $67.66 +1.11%
Rating Summary:
12 Buy, 22 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 11 | New: 32
Rating Summary:
12 Buy, 22 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 11 | New: 32
Join SI Premium – FREE
Citi analyst Andrew Baum downgraded Bristol-Myers Squibb Co. (NYSE: BMY) from Buy to Neutral with a price target of $57.00 (from $62.00).
For an analyst ratings summary and ratings history on Bristol-Myers Squibb Co. click here. For more ratings news on Bristol-Myers Squibb Co. click here.
Shares of Bristol-Myers Squibb Co. closed at $53.18 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wedbush Downgrades Tscan Therapeutics Inc (TCRX) to Neutral
- Comstock Resources (CRK) PT Raised to $17 at BMO Capital
- BMS presents five-year Camzyos data for heart condition at ESC
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
